IPSEN : Innovation for patient care

 GO TO

THE IPSEN GROUP
 
CONTACT

Info

Ipsen Pty Ltd

Focus

About Ipsen Pty Ltd

Ipsen Pty Ltd is the Australian affiliate of a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2010. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2010, R&D expenditure totaled more than €220 million, above 20% of Group sales. The Group has total worldwide staff of close to 4,500 employees.

Our Products

Dysport® - Clostridium botulinum type A toxin-haemagglutinin complex

CMI

Somatuline® autogel® - lanreotide

CMI

Somatuline® LA - lanreotide

CMI

Diphereline® triptorelin embonate

CMI

NutropinAq® - Somatropin, recombinant DNA origin, Escherichia coli

CMI


The material provided on this website is for your information only and does not replace the advice provided by your doctor and/or pharmacist. If you have any questions or require advice about medicines that you have been prescribed, please discuss these with your doctor or pharmacist. The information provided on this page is intended for use in Australia only.

Please carefully read the website Terms as they determine the conditions of use of this site which you accept and agree by consulting and using our site. If you do not accept these Terms, we ask you to leave our site.

Address